Whether Quantum-Si stock has a viable long-term future depends entirely on its ability to successfully commercialize its next-generation protein sequencing platforms, drive widespread laboratory adoption of its consumables, and achieve sustainable revenue scaling before its cash reserves deplete. While its disruptive semiconductor proteomics approach holds massive scientific promise, its future equity performance remains tied to flawless operational execution through its transitional phases.